India · Delayed Price · Currency is INR Krishna Institute of Medical Sciences Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 35% year-over-year in Q4 FY26, but EBITDA margin declined due to new unit ramp-up and insurance empanelment delays. Mature units maintained strong margins, while new units are expected to turn EBITDA positive within a year. Debt reduction and continued expansion in core markets are planned.
-
Q3 FY 2026 saw record revenue growth of 29.2% YoY, surpassing INR 1,000 crore, despite EBITDA margin compression due to new unit ramp-ups. New hospitals are stabilizing, with break-even targeted in FY 2027, and debt levels expected to moderate as expansion slows.
-
Revenue grew 23% year-over-year, but EBITDA and margins declined due to ramp-up costs from new hospitals. Management expects margin expansion as new units reach break-even, with ARPOB and specialty mix set to improve. Andhra Pradesh and Telangana clusters remain strong.
-
Revenue grew 26.8% YoY to INR 879 crore, with EBITDA at INR 200 crore and margin at 22.7%. New units in Thane, Bangalore, and Kerala are ramping up, with initial losses expected to neutralize within 12 months. Net debt stands at INR 2,020 crore, and ARPOB is projected to rise as new facilities mature.
Fiscal Year 2025
-
FY25 delivered robust revenue and EBITDA growth, driven by mature clusters and new hospital launches. Margin expansion was supported by higher ARPOB, specialty mix, and technology adoption, with new units expected to turn EBITDA positive within a year.
-
Revenue grew 29.7% year-over-year to INR 790 crore, with EBITDA up 36.4% and margin at 25.9%. Expansion continues in Kerala, Maharashtra, and Bangalore, with new hospitals and clinical milestones achieved. Debt and CapEx remain within guided levels, and margins are expected to improve as new specialties ramp up.
-
Revenue and EBITDA grew strongly year-on-year, with margins improving to 28.5%. Expansion in Kerala and Andhra Pradesh is underway via asset-light and O&M models, with a focus on maintaining leverage and margins. Strategic partnerships and clinical achievements support future growth.
-
Revenue and EBITDA grew strongly year-over-year, with ARPOB and margins improving. Expansion continues with new acquisitions and hospital launches, while debt and CapEx are managed within set limits. Margin sustainability is expected despite new hospital drag.